Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

GLYC


Fundamental

Company: Crescent Biopharma Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: Small
Index: -
P/E: -
EPS (ttm): -12.48
Insider Own: 22.70%
Shs Outstand: 27.57M
Perf Week: 8.58%
Market Cap: 540.69M
Forward P/E: -
EPS next Y: -3.25
Insider Trans: 27.76%
Shs Float: 21.31M
Perf Month: 0.46%
Enterprise Value: 357.07M
PEG: -
EPS next Q: -0.78
Inst Own: 74.11%
Short Float: 11.24%
Perf Quarter: 107.51%
Income: -162.08M
P/S: 45.51
EPS this Y: 75.02%
Inst Trans: 45.71%
Short Ratio: 9.58
Perf Half Y: 49.58%
Sales: 11.88M
P/B: 3.01
EPS next Y Percentage: -1.49%
ROA: -158.03%
Short Interest: 2.40M
Perf YTD: 65.35%
Book/sh: 6.52
P/C: 2.86
EPS next 5Y: 35.34%
ROE: -173.14%
52W High: 27.50 -28.69%
Perf Year: -22.46%
Cash/sh: 6.86
P/FCF: -
EPS past 3/5Y: 45.01% 33.26%
ROIC: -87.64%
52W Low: 8.72 124.89%
Perf 3Y: -89.79%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: 424.86% 1.31%
Gross Margin: 98.75%
Volatility W: 10.08%
Volatility M: 12.38%
Perf 5Y: -92.22%
Dividend TTM: -
EV/Sales: 30.06
EPS Y/Y TTM: 72.70%
Oper. Margin: -1372.85%
ATR (14): 2.19
Perf 10Y: -96.89%
Dividend Ex-Date: -
Quick Ratio: 13.78
Sales Y/Y TTM: -100.00%
Profit Margin: -1363.94%
RSI (14): 51.27
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 13.78
EPS Q/Q: 78.91%
SMA20: -7.14%
Beta: 1.17
Target Price: 29.50
Payout: -
Debt/Eq: 0.01
Sales Q/Q: -
SMA50: 14.24%
Rel Volume: 1.01
Prev Close: 18.46
Employees: 44
LT Debt/Eq: 0.01
Earnings: Apr 29 AMC
SMA200: 44.46%
Avg Volume: 249.89K
Price: 19.61
IPO: Jan 10, 2014
Option/Short: No / Yes
EPS/Sales Surpr.: 20.33% 180.03%
Trades:
Volume: 251,890
Change: 6.23%

Technical:


Latest News:

Glycobiology/Glycomics Market 2024 Growth Parameters – Thermo Fisher Scientific, Agilent ... somewhat bullish
TMO A EW WAT BRKR SIAL 7986JP PROZ DHR 7701JP

Summary: A new research report titled Global Glycobiology/Glycomics Market provides an in-depth analysis of a global market summarizing key uses, growth analysis, industry trends, and forecasts to 2032. The report offers a detailed picture of the current industrial situation incorporating authentic and anticipated market estimates in terms of value and volume. The report also includes a full analysis of raw material sourcing, significant suppliers, raw material price patterns, and an examination of the industrial chain.

Full article
2024-09-19T05:48:31Z
Capital One Financial Comments on GlycoMimetics, Inc.'s Q1 2024 Earnings (NASDAQ:GLYC) somewhat bearish
GLYC

Summary: Capital One Financial issued Q1 2024 EPS estimates for GlycoMimetics with a 'Equal Weight' rating. The consensus estimate for GlycoMimetics' full-year earnings is ($0.54) per share. Several brokerages commented on GLYC, with StockNews.com downgrading it and HC Wainwright maintaining a 'neutral' rating.

Full article
2024-05-09T10:51:04Z
Dow Launches Bio-Circular and Circular Propylene Glycol Solutions in North America somewhat bullish
DOW

Summary: Dow (NYSE: DOW) launches two new sustainable varieties of propylene glycol solutions in North America, featuring bio-circular and circular feedstocks, aiming to offer high-performance products with sustainability benefits.

Full article
2024-05-07T17:18:24Z